← Back to Search

Anti-cancer Agent

Treatment for Breast Cancer

N/A
Recruiting
Led By Leslie Montgomery, MD
Research Sponsored by Hackensack Meridian Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up completion of chemotherapy, approximately 18 weeks.
Awards & highlights
No Placebo-Only Group

Summary

The probability of pCR in TNBC patients receiving standard of care neoadjuvant chemotherapy treatment is associated with the dominance of specific intestinal and intratumoral microbiota that promote anti-tumor immunosurveillance.

Eligible Conditions
  • Breast Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~completion of chemotherapy, approximately 18 weeks.
This trial's timeline: 3 weeks for screening, Varies for treatment, and completion of chemotherapy, approximately 18 weeks. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Pathologic Complete Response
Secondary study objectives
Other Correlations between Pathologic complete Response

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Find a Location

Who is running the clinical trial?

Hackensack Meridian HealthLead Sponsor
135 Previous Clinical Trials
30,253 Total Patients Enrolled
7 Trials studying Breast Cancer
2,304 Patients Enrolled for Breast Cancer
Breast Cancer Research FoundationOTHER
71 Previous Clinical Trials
137,774 Total Patients Enrolled
42 Trials studying Breast Cancer
130,509 Patients Enrolled for Breast Cancer
Leslie Montgomery, MDPrincipal InvestigatorHackensack UMC
1 Previous Clinical Trials
13 Total Patients Enrolled
1 Trials studying Breast Cancer
13 Patients Enrolled for Breast Cancer
~1 spots leftby Jan 2025